Influence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodeficiency virus patients

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 7, 2009, Pages 2791-2798

  Cabrera, Salvador E ^a,b   Santos, Dolores ^c   Valverde, María P ^a   Domínguez Gil, Alfonso ^a,c   González, Francisco ^c   Luna, Guillermo ^a   García, María J ^c  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b UNIVERSIDAD AUSTRAL DE CHILE   (Chile)

^c UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2B6; CYTOCHROME P450 3A4; EFAVIRENZ; MULTIDRUG RESISTANCE PROTEIN 1;

ADULT; AGE; ARTICLE; BAYES THEOREM; BODY HEIGHT; BODY MASS; BODY WEIGHT; COMPARTMENT MODEL; DISTRIBUTION VOLUME; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; FEMALE; GENDER; GENETIC POLYMORPHISM; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; POPULATION MODEL; PRIORITY JOURNAL;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AGE FACTORS; ARYL HYDROCARBON HYDROXYLASES; BENZOXAZINES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; GENOTYPE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; OXIDOREDUCTASES, N-DEMETHYLATING; POLYMORPHISM, GENETIC; SEX FACTORS;

EID: 67649960169     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01537-08     Document Type: Article

References (48)

1. Adkins, J. C., and S. Noble. 1998. Efavirenz. Drugs 56:1055-1064.
2. Alexander, C. S., J. J. Asselin, L. S. Ting, J. S. Montaner, R. S. Hogg, B. Yip, M. V. O'Shaughnessy, and P. R. Harrigan. 2003. Antiretroviral concentrations in untimed plasma samples predict therapy outcome in a population with advanced disease. J. Infect. Dis. 188:541-548.
3. Barret, J. S. 2002. Population pharmacokinetics, p. 315-356. In R. D. Schoenwald (ed.), Pharmacokinetics in drug discovery and development. CRC Press LLC, Boca Raton, FL.
4. Barrett, J. S., A. S. Joshi, M. Chai, T. M. Ludden, W. D. Fiske, and H. J. Pieniaszek, Jr. 2002. Population pharmacokinetic meta-analysis with efavirenz. Int. J. Clin. Pharmacol. Ther. 40:507-519.
5. Barrett, J. S., L. Labbé, and M. Pfister. 2005. Application and impact of population pharmacokinetics in the assessment of antiretroviral pharmacotherapy. Clin. Pharmacokinet. 44:591-625.
6. Cabrera, S., M. Cordero, A. Iglesias, M. P. Valverde, A. Domínguez-Gil, and M. J. García. 2008. Efavirenz-rifampicin interaction: therapeutic drug monitoring to efavirenz dosage optimization in HIV/TBC patients. AIDS 22: 2549-2551.
7. Christians, U., W. Jacobsen, L. Z. Benet, and A. Lampen. 2002. Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin. Pharmacokinet. 41:813-851.
8. Clevenbergh, P., S. Mouly, P. Sellier, E. Badsi, J. Cervoni, V. Vincent, H. Trout, and J. F. Bergmann. 2004. Improving HIV infection management using antiretroviral plasma drug levels monitoring: a clinician's point of view. Curr. HIV Res. 2:309-321.
9. Colombo, S., N. Guignard, C. Marzolini, A. Telenti, J. Biollaz, and L. A. Decosterd. 2004. Determination of the new HIV-protease inhibitor atazanavir by liquid chromatography after solid-phase extraction. J. Chromatogr. B 810:25-34.
10. Comets, E., K. Ikeda, P. Hoff, P. Fumoleau, J. Wanders, and Y. Tanigawara. 2003. Comparison of the pharmacokinetics of S-1, an oral anticancer agent, in Western and Japanese patients. J. Pharmacokinet. Pharmacodyn. 30:257-283.
11. Csajka, C., C. Marzolini, K. Fattinger, L. A. Décosterd, J. Fellay, A. Telenti, J. Biollaz, and T. Buclin. 2003. Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Clin. Pharmacol. Ther. 73:20-30.
12. Dahri, K., and M. H. Ensom. 2007. Efavirenz and nevirapine in HIV-1 infection: is there a role for clinical pharmacokinetic monitoring? Clin. Pharmacokinet. 46:109-132.
13. Dasgupta, A., and P. C. Okhuysen. 2001. Pharmacokinetic and other drug interactions in patients with AIDS. Ther. Drug Monit. 23:591-605.
14. Duong, M., A. Golzi, G. Peytavin, L. Piroth, M. Froidure, M. Grappin, M. Buisson, E. Kohli, P. Chavanet, and H. Portier. 2004. Usefulness of therapeutic drug monitoring of antiretrovirals in routine clinical practice. HIV Clin. Trials 5:216-223.
15. Ensom, M. H., G. A. Davis, C. D. Cropp, and R. J. Ensom. 1998. Clinical pharmacokinetics in the 21st century. Does the evidence support definitive outcomes? Clin. Pharmacokinet. 34:265-279.
16. Fellay, J., C. Marzolini, E. R. Meaden, D. J. Back, T. Buclin, J. P. Chave, L. A. Decosterd, H. Furrer, M. Opravil, G. Pantaleo, D. Retelska, L. Ruiz, A. H. Schinkel, P. Vernazza, C. B. Eap, A. Telenti, and Swiss HIV Cohort Study. 2002. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 359:30-36.
17. Gatanaga, H., T. Hayashida, K. Tsuchiya, M. Yoshino, T. Kuwahara, H. Tsukada, K. Fujimoto, I. Sato, M. Ueda, M. Horiba, M. Hamaguchi, M. Yamamoto, N. Takata, A. Kimura, T. Koike, F. Gejyo, S. Matsushita, T. Shirasaka, S. Kimura, and S. Oka. 2007. Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26. Clin. Infect. Dis. 45:1230-1237.
18. González de Requena, D., S. Bonora, S. Garazzino, M. Sciandra, A. D'Avolio, R. Raiteri, R. Marrone, M. Boffito, F. G. De Rosa, A. Sinicco, and G. Di Perri. 2005. Nevirapine plasma exposure affects both durability of viral suppression and selection of nevirapine primary resistance mutations in a clinical setting. Antimicrob. Agents Chemother. 49:3966-3969.
19. Haas, D. W. 2005. Will pharmacogenomic discoveries improve HIV therapeutics? Top. HIV Med. 13:90-95.
20. Haas, D. W., H. J. Ribaudo, R. B. Kim, C. Tierney, G. R. Wilkinson, R. M. Gulick, D. B. Clifford, T. Hulgan, C. Marzolini, and E. P. Acosta. 2004. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS 18:2391-2400.
21. Haas, D. W., L. M. Smeaton, R. W. Shafer, G. K. Robbins, G. D. Morse, L. Labbe, G. R. Wilkinson, D. B. Clifford, R. T. D'Aquila, V. De Gruttola, R. B. Pollard, T. C. Merigan, M. S. Hirsch, A. L. George, Jr., J. P. Donahue, and R. B. Kim. 2005. Pharmacogenetics of long-term responses to antiretroviral regimens containing efavirenz and/or nelfinavir: an Adult AIDS Clinical Trials Group study. J. Infect. Dis. 192:1931-1942.
22. Hirsch, M., S. Hirsch, B. Conway, R. T. D'Aquila, V. A. Johnson, F. Brun-Vézinet, B. Clotet, L. M. Demeter, S. M. Hammer, D. M. Jacobsen, D. R. Kuritzkes, C. Loveday, J. W. Mellors, S. Vella, D. D. Richman, et al. 1998. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. JAMA 279:1984-1991.
23. Jonsson, E. N., and M. O. Karlsson. 1999. Xpose-an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput. Methods Programs Biomed. 58:51-64.
24. Kappelhoff, B. S., A. D. Huitema, Z. Yalvaç, J. M. Prins, J. W. Mulder, P. L. Meenhorst, and J. H. Beijnen. 2005. Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals. Clin. Pharmacokinet. 44:849-861.
25. Kappelhoff, B. S., F. van Leth, T. R. MacGregor, J. Lange, J. H. Beijnen, A. D. Huitema, and 2NN Study Group. 2005. Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study. Antivir. Ther. 10:145-155.
26. Knobel, H., J. Alonso, J. L. Casado, J. Collazos, J. González, I. Ruiz, J. M. Kindelan, A. Carmona, J. Juega, A. Ocampo, and GEEMA Study Group. 2002. Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: the GEEMA Study. AIDS 16:605-613.
27. Marzolini, C., A. Telenti, L. A. Decosterd, G. Greub, J. Biollaz, and T. Buclin. 2001. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 15:71-75.
28. Mesnil, F., F. Mentré, C. Dubruc, J. P. Thénot, and A. Mallet. 1998. Population pharmacokinetic analysis of mizolastine and validation from sparse data on patients using the nonparametric maximum likelihood method. J. Pharmacokinet. Biopharm. 26:133-161.
29. Noormohamed, S. E., W. K. Henry, F. S. Rhame, C. V. Balfour, Jr., and H. H. Fletcher. 1995. Strategies for control of zidovudine concentrations in serum. Antimicrob. Agents Chemother. 39:2792-2797.
30. Núñez, M., D. González de Requena, L. Gallego, I. Jiménez-Nácher, J. González-Lahoz, and V. Soriano. 2001. Higher efavirenz plasma levels correlate with development of insomnia. J. Acquir. Immune Defic. Syndr. 28: 399-400.
31. Nyakutira, C., D. Röshammar, E. Chigutsa, P. Chonzi, M. Ashton, C. Nhachi, and C. Masimirembwa. 2008. High prevalence of the CYP2B6 516G→T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe. Eur. J. Clin. Pharmacol. 64:357-365.
32. Perry, C. M., and J. A. Balfour. 1996. Didanosine. An update on its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV disease. Drugs 52:928-962.
33. Pfister, M., L. Labbé, S. M. Hammer, J. Mellors, K. K. Bennett, S. Rosenkranz, L. B. Sheiner, and Adult AIDS Clinical Trial Group study 398. 2003. Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group study 398. Antimicrob. Agents Chemother. 47:130-137.
34. Ribaudo, H. J., D. W. Haas, C. Tierney, R. B. Kim, G. R. Wilkinson, R. M. Gulick, D. B. Clifford, C. Marzolini, C. V. Fletcher, K. T. Tashima, D. R. Kuritzkes, E. P. Acosta, and Adult AIDS Clinical Trials Group study. 2006. Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group study. Clin. Infect. Dis. 42:401-407.
35. Rodríguez-Nóvoa, S., P. Barreiro, I. Jiménez-Nácher, and V. Soriano. 2006. Overview of the pharmacogenetics of HIV therapy. Pharmacogenomics J. 6:234-245.
36. Saitoh, A., K. K. Singh, C. A. Powell, T. Fenton, C. V. Fletcher, R. Brundage, S. Starr, and S. A. Spector. 2005. An MDR1-3435 variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children. AIDS 19:371-380.
37. Shimada, T., H. Yamazaki, M. Mimura, Y. Inui, and F. P. Guengerich. 1994. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 270:414-423.
38. Soldin, O. P., R. J. Elin, and S. J. Soldin. 2003. Therapeutic drug monitoring in human immunodeficiency virus/acquired immunodeficiency syndrome. Quo vadis? Arch. Pathol. Lab. Med. 127:102-105.
39. Sowunmi, A., T. J. Rashid, O. O. Akinyinka, and A. G. Renwick. 1995. Ethnic differences in nifedipine kinetics: comparisons between Nigerians, Caucasians and South Asians. Br. J. Clin. Pharmacol. 40:489-493.
40. Stahle, L., L. Moberg, J. O. Svensson, and A. Sönnerborg. 2004. Efavirenz plasma concentrations in HIV-infected patients: inter- and intraindividual variability and clinical effects. Ther. Drug Monit. 26:267-270.
41. Stöhr, W., D. Back, D. Dunn, C. Sabin, A. Winston, R. Gilson, D. Pillay, T. Hill, J. Ainsworth, A. Pozniak, C. Leen, L. Bansi, M. Fisher, C. Orkin, J. Anderson, M. Johnson, P. Easterbrook, S. Gibbons, S. Khoo, Liverpool TDM Database, and UK CHIC study. 2008. Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and comedication. Antivir. Ther. 13:675-685.
42. Tejedor, D., S. Castillo, P. Mozas, E. Jiménez, M. López, M. T. Tejedor, M. Artieda, R. Alonso, P. Mata, L. Simón, A. Martínez, M. Pocoví, and Spanish FH Group. 2005. Reliable low-density DNA array based on allele-specific probes for detection of 118 mutations causing familial hypercholesterolemia. Clin. Chem. 51:1137-1144.
43. Van Heeswijk, R. P. 2002. Critical issues in therapeutic drug monitoring of antiretroviral drugs. Ther. Drug Monit. 24:323-331.
44. Vanhove, G. F., J. M. Schapiro, M. A. Winters, T. C. Merigan, and T. F. Blaschke. 1996. Patient compliance and drug failure in protease inhibitor monotherapy. JAMA 276:1955-1956.
45. Villani, P., M. B. Regazzi, F. Castelli, P. Viale, C. Torti, E. Seminari, and R. Maserati. 1999. Pharmacokinetics of efavirenz (EFV) alone and in combination therapy with nelfinavir (NFV) in HIV-1 infected patients. Br. J. Clin. Pharmacol. 48:712-715.
46. Wade, J. R., A. W. Kelman, C. A. Howie, and B. Whiting. 1993. Effect of misspecification of the absorption process on subsequent parameter estimation in population analysis. J. Pharmacokinet. Biopharm. 21:209-222.
47. Wainberg, M. A., and G. Friedland. 1998. Public health implications of antiretroviral therapy and HIV drug resistance. JAMA 279:1977-1983.
48. Winzer, R., P. Langmann, M. Zilly, F. Tollmann, J. Schubert, H. Klinker, and B. Weissbrich. 2003. No influence of the P-glycoprotein genotype (MDR1 C3435T) on plasma levels of lopinavir and efavirenz during antiretroviral treatment. Eur. J. Med. Res. 8:531-534.